BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Febit, Inc. Launches New Instrument for Targeted NextGen Sequencing With High Sample Throughput at AGBT Conference


2/17/2010 9:54:44 AM

Bookmark and Share

LEXINGTON, Mass. and HEIDELBERG, Germany, Feb. 17 /PRNewswire/ -- febit today announced the launch of its HybSelector, a new instrument for high throughput targeted resequencing, at the 11th annual Advances in Genome Biology and Technology (AGBT) meeting on February 24-27, 2010, in Marco Island, Florida. AGBT is now widely regarded as the premier scientific forum for sharing information about the latest advances in new DNA sequencing technologies and their application to diverse areas in biology and biomedical research.

The new HybSelector instrument will replace the Geniom RT Analyzer for high-quality DNA enrichment followed by targeted next-generation sequencing. The compact HybSelector combines febit's well established expertise in the development and manufacture of technologies for genome exploration with the most advanced high-quality DNA enrichment automation available on the market.

"The HybSelector features all technical components necessary for HybSelect, our DNA enrichment protocol," said Peer Staehler, CSO at febit. "We are able to offer the HybSelector at a very competitive price. This will enable the large genomics research community, which has already indicated a high interest in affordable targeted re-sequencing solutions, to use HybSelect's high sample throughput at low acquisition costs."

The economic benefit of HybSelect increases the potential for widespread use of next generation sequencing in clinical studies. Instead of sequencing the complete genomes of only a limited number of patients, HybSelect enables the analysis of specific genes of interest from large patient cohorts for the same price and data management effort. The larger patient pool now provides the statistically relevant data that are necessary for clinical studies.

About febit

febit develops, produces and markets flexible automated solutions for enabling biochip applications in Life Sciences. febit's product portfolio includes various instruments, optimized assays and bioanalytical services, complemented by bioinformatics software and consulting.

The key applications are HybSelect, febit's innovative DNA capture method for Next-Generation-Sequencing, and hands-off, amplification free microRNA profiling. Both are taking advantage of the advanced microfluidics of the patented Geniom Biochip to offer the highest degree of automation, flexibility and efficiency available.

For more information, please visit www.febit.com.

Contact: febit group, Eva Sterzel, eva.sterzel@febit.de, +49 (0)6221 6510-300 Russo Partners, Martina Schwarzkopf, martina.schwarzkopf@russopartnersllc.com, +1 212 845-4292 SOURCE febit

RELATED LINKS http://www.febit.com

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES